Background: Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia,
is increasingly used for off-label indications. Purpose: To evaluate the benefits and harms of …

Over 35 000 cardiac operations using cardiopulmonary bypass are performed annually in
the UK. Post‐operative bleeding is a common cause of morbidity. Although there have been …

BACKGROUND: Numerous studies have supported the effectiveness of recombinant
activated factor VII (rFVIIa) for the control of bleeding after cardiac procedures; however …

Background: Severe or massive bleeding in cardiac surgery is an uncommon but important
clinical scenario. Its existing definitions are diverse. Its characteristics constantly change …

Background Bleeding after surgery on the thoracic aorta is a frequent complication, and can
be associated with a significant increase in morbidity and mortality. Recombinant activated …

Purpose An innovative pharmacist-led program to improve prescribing, dosing, and
monitoring of clotting factor therapy within a large health system is described. Summary In …

The design and implementation of massive transfusion protocols with ratio-based
transfusion of blood and blood products are important and active areas of investigation. A …

Objectives: The study aimed to describe French off-label use of rFVIIa for intractable
bleeding in major cardiovascular surgery. Methods: Retrospective observational analysis of …

OBJECTIVES Postoperative bleeding is a common cause of morbidity and mortality in
cardiac patients who undergo cardiopulmonary bypass (CPB). Pediatric patients are …

Background: Medically refractory hemorrhage in patients on ECMO (extracorporeal
membrane oxygenation) support can have catastrophic complications. Recombinant …